When a heart attack strikes, the standard playbook is balloon angioplasty and stenting to restore blood flow. But what if clearing the clot first could protect more of the heart muscle? That's the idea behind the NATURE trial, which tested stent retriever thrombectomy — a clot-removal device (enVast, Vesalio) — before conventional PCI in STEMI patients with large thrombus burdens.

The results, presented at the European Society of Cardiology Congress and published in the Journal of the American College of Cardiology, are encouraging. Removing the clot before stenting significantly reduced infarct size, suggesting the technique helps prevent clot fragments from being pushed into smaller vessels and damaging the heart muscle further.

By the Numbers:

• 26% reduction in infarct size (measured by creatine kinase-MB area under the curve) in the thrombectomy + PCI group vs. PCI alone (3,965 vs. 5,250 IU/L per hour; P = .001)
• 25% smaller infarct size on cardiac MRI in the thrombectomy group (17% vs. 28%)
• 0 device-related serious adverse events in the retriever group
• 156 patients enrolled, all presenting within 8 hours of symptom onset

Why it matters: Infarct size is a key predictor of long-term heart function and outcomes after a heart attack. A 26% reduction is clinically meaningful, and the strong safety profile makes this approach a compelling candidate for broader adoption — though researchers note further studies are needed to confirm improved long-term clinical outcomes.